Takeda Pharmaceutical Company Limited (TAK)
- Zacks
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
- Business Wire
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
WORCESTER, Mass., October 13, 2021--BioLife Plasma Services announces new center opening in Worcester, MA to support an urgent need for plasma donations.
- Business Wire
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
OSAKA, Japan & CAMBRIDGE, Mass., October 07, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimo
